Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

The rationale and ethics of medication-free research in schizophrenia.

Carpenter WT Jr, Schooler NR, Kane JM.

Arch Gen Psychiatry. 1997 May;54(5):401-7. Review.

PMID:
9152092
2.

Ethical concerns about relapse studies.

Shamoo AE, Keay TJ.

Camb Q Healthc Ethics. 1996 Summer;5(3):373-86. Review. No abstract available.

PMID:
8862824
3.

Informed consent for psychiatric research: the case of medication-free research.

Berghmans RL.

Med Law. 1999;18(4):515-24. Review.

PMID:
10687359
4.

Addressing the ethical challenges of clinical trials that involve patients with dementia.

Karlawish JH, Casarett D.

J Geriatr Psychiatry Neurol. 2001 Winter;14(4):222-8. Review.

PMID:
11794450
5.

The risk of medication-free research.

Carpenter WT Jr.

Schizophr Bull. 1997;23(1):11-8. Review.

6.

Consent to neuroleptic medication for schizophrenia: clinical, ethical and legal issues.

Brabbins C, Butler J, Bentall R.

Br J Psychiatry. 1996 May;168(5):540-4. Review.

PMID:
8733791
7.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
8.
9.

The use of placebos in clinical trials for acute schizophrenia.

Addington D.

Can J Psychiatry. 1995 May;40(4):171-6. Review.

PMID:
7621385
10.

Consent in Alzheimer's disease research: risk/benefit factors.

Beattie BL.

Can J Neurol Sci. 2007 Mar;34 Suppl 1:S27-31. Review.

PMID:
17469678
11.

Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.

Woods SW, Gueorguieva RV, Baker CB, Makuch RW.

Arch Gen Psychiatry. 2005 Sep;62(9):961-70. Review.

PMID:
16143728
12.

Ethics of clinical trials.

Iyalomhe GB, Imomoh PA.

Niger J Med. 2007 Oct-Dec;16(4):301-6. Review.

PMID:
18080584
13.

Ethical considerations in psychopharmacological research involving decisionally impaired subjects.

Rosenstein DL, Miller FG.

Psychopharmacology (Berl). 2003 Dec;171(1):92-7. Review.

PMID:
12774188
14.

Benefits and burdens of placebos in psychiatric research.

Kim SY.

Psychopharmacology (Berl). 2003 Dec;171(1):13-8. Review.

PMID:
12684741
15.

Ethical challenges in neonatal research: Summary report of the ethics group of the newborn drug development initiative.

Baer GR, Nelson RM; Ethics Group of the Newborn Drug Development Initiative..

Clin Ther. 2006 Sep;28(9):1399-407. Review.

PMID:
17062312
16.

Who is my brother's keeper?

Kottow MH.

J Med Ethics. 2002 Feb;28(1):24-7. Review.

17.

Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature.

Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV.

J Clin Psychiatry. 2002 Oct;63(10):892-909. Review.

PMID:
12416599
18.

Ethical considerations for the conduct of antidementia trials in Canada.

Fisk JD.

Can J Neurol Sci. 2007 Mar;34 Suppl 1:S32-6. Review.

PMID:
17469679
19.

Good clinical practice, a transparent way of life. A review.

van Dongen AJ.

Comput Med Imaging Graph. 2001 Mar-Apr;25(2):213-6. Review.

PMID:
11137799
20.
Items per page

Supplemental Content

Support Center